ACTIVE_NOT_RECRUITING

Healthy Opioid Prescription Engagement

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is a randomized controlled trial across 14 community pharmacies to test the efficacy of the Brief Intervention-Medication Therapy Management intervention (BI-MTM). The establishment of the BI-MTM model will result in a major impact for addressing the opioid epidemic, preventing opioid use disorder and overdose, and safeguarding patient health in a novel community-based service setting.

Official Title

Healthy Opioid Prescription Engagement 2.0

Quick Facts

Study Start:2021-11-08
Study Completion:2026-07-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05141266

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult (≥18 years)
  2. * English speaking
  3. * Not receiving cancer treatment
  4. * Who have a positive opioid misuse screen on the POMI will be eligible to learn about this study
  1. * Are pregnant (given potential pre/post-natal opioid use complications among pregnant women/offspring
  2. * Can-not provide collateral contact information for ≥2 contact persons (to ensure consistent contact/follow up)
  3. * Do not have a reliable land line or mobile phone to be contacted by study staff
  4. * Are filling only buprenorphine (given some formulations are not indicated for pain)
  5. * Plan to leave the area for an extended period of time in the next 6 months
  6. * Have had a psychotic and/or manic episode in the last 30 days (before consent, patients will be asked to screen for psychosis
  7. * Do not provide permission to access their state prescription drug monitoring data.

Contacts and Locations

Principal Investigator

Gerald Cochran, PhD
PRINCIPAL_INVESTIGATOR
University of Utah

Study Locations (Sites)

University of Utah
Salt Lake City, Utah, 84108
United States

Collaborators and Investigators

Sponsor: Jerry Cochran

  • Gerald Cochran, PhD, PRINCIPAL_INVESTIGATOR, University of Utah

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-08
Study Completion Date2026-07-01

Study Record Updates

Study Start Date2021-11-08
Study Completion Date2026-07-01

Terms related to this study

Keywords Provided by Researchers

  • Community Pharmacies
  • Patient Navigation
  • Opioid intervention

Additional Relevant MeSH Terms

  • Opioid Misuse
  • Opioid-Related Disorders
  • Pharmacist-Patient Relations